Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 3/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356269 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL3383102 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL9352420 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL9663087 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL7824358 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL3381106 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL517169 | 0.98 | HDAC1 (0.96) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL6604478 | 0.96 | HDAC1 (0.92) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL503304 | 0.93 | HDAC1 (0.88) | HDAC1HDAC8HDAC3HDAC2HDAC4 | |
| SCHEMBL8519287 | 0.93 | TDP1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | claimed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116897206-A | Oral delivery of PCSK 9-targeting antisense conjugates | 四纬生物制药股份有限公司 | 2023-10-17 | — | — | CN | claimed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | claimed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | claimed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| CN-102516067-A | Method for synthesizing seratrodast intermedia 6-benzoyl hexanoic acid | UNIV YIBIN | 2012-06-27 | — | — | CN | claimed |
| CN-1984864-B | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECH INC | 2011-02-09 | — | — | CN | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| US-6861550-B2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2005-03-01 | — | — | US | claimed |
| US-20030100084-A1 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2003-05-29 | — | — | US | claimed |
| EP-1130042-A2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2001-09-05 | — | — | EP | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117545509-A | Oral delivery of oligonucleotides | 四纬生物制药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116897206-A | Oral delivery of PCSK 9-targeting antisense conjugates | 四纬生物制药股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023287964-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-2897620-B1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-2661265-B1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9290453-B2 | Quinolines and aza-quinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2661265-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296300-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| WO-2012087872-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-102516067-A | Method for synthesizing seratrodast intermedia 6-benzoyl hexanoic acid | UNIV YIBIN | 2012-06-27 | — | — | CN | disclosed |
| CN-102516067-A | Method for synthesizing seratrodast intermedia 6-benzoyl hexanoic acid | UNIV YIBIN | 2012-06-27 | — | — | CN | disclosed |
| CN-102516067-A | Method for synthesizing seratrodast intermedia 6-benzoyl hexanoic acid | UNIV YIBIN | 2012-06-27 | — | — | CN | disclosed |
| US-20110165699-A1 | IRINOTECAN IMMUNOASSAY | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-07-07 | — | — | US | disclosed |
| US-20110136253-A1 | Irinotecan Immunoassay | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-06-09 | — | — | US | disclosed |
| CN-1984864-B | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECH INC | 2011-02-09 | — | — | CN | disclosed |
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100245-A1 | LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100245-A1 | LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| CN-100360512-C | Biphenylmethyl-thiazolidinediones and analogues thereof and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2008-01-09 | — | — | CN | disclosed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| CN-1984864-A | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1745004-A4 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1745004-A2 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7122564-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-17 | — | — | US | disclosed |
| WO-2005117854-A2 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| CN-1639138-A | Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2005-07-13 | — | — | CN | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| US-6861550-B2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2005-03-01 | — | — | US | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030100084-A1 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| EP-1130042-A2 | Polyhydroxyalkanoate containing 3-hydroxybenzoylalkanoic acid as monomer unit, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0412933-B1 | Coating compositions | CIBA GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| US-5183842-A | Mixture of ketoacid and amine with film-forming binder, curing | CIBA-GEIGY CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-5128396-A | Corrosion inhibiting primers on metallic substrates | CIBA-GEIGY CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0412933-A1 | Coating compositions | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
| EP-0412933-A1 | Coating compositions | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | HDAC1 269/4885HDAC8 324/4885HDAC3 379/4885 |
| US-20110165699-A1 | IRINOTECAN IMMUNOASSAY | SI, TOP2A, TYMP | HDAC1 2399/4885HDAC8 1806/4885HDAC3 2768/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | HDAC1 2555/4885HDAC8 806/4885HDAC3 1577/4885 |
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HDAC1 56/4885HDAC8 45/4885HDAC3 88/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HDAC1 56/4885HDAC8 45/4885HDAC3 88/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | HDAC1 424/4885HDAC8 235/4885HDAC3 74/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | HDAC1 1193/4885HDAC8 201/4885HDAC3 355/4885 |
| US-20020115826-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885 |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | HDAC1 1193/4885HDAC8 201/4885HDAC3 355/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | HDAC1 424/4885HDAC8 235/4885HDAC3 74/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | HDAC1 1193/4885HDAC8 201/4885HDAC3 355/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | HDAC1 269/4885HDAC8 324/4885HDAC3 379/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | HDAC1 1680/4885HDAC8 2771/4885HDAC3 2064/4885 |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC8 9/4885HDAC3 3/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | HDAC1 305/4885HDAC8 387/4885HDAC3 438/4885 |
| US-20130296300-A1 | QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | HDAC1 938/4885HDAC8 1671/4885HDAC3 845/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | HDAC1 84/4885HDAC8 1034/4885HDAC3 70/4885 |
| US-20110136253-A1 | Irinotecan Immunoassay | SI, TOP2A, TYMP | HDAC1 2399/4885HDAC8 1806/4885HDAC3 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.